DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Saturday morning. The firm issued a hold rating on the stock.

Several other research analysts also recently commented on DBVT. JMP Securities reiterated a market outperform rating and set a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th. HC Wainwright reiterated a buy rating and issued a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st.

DBV Technologies Trading Up 5.2 %

NASDAQ DBVT opened at $0.72 on Friday. DBV Technologies has a 12 month low of $0.50 and a 12 month high of $2.50. The stock has a 50 day moving average of $0.83 and a 200-day moving average of $1.03. The company has a market cap of $69.02 million, a PE ratio of -0.85 and a beta of 0.67.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same quarter in the prior year, the business earned ($0.26) EPS. As a group, sell-side analysts predict that DBV Technologies will post -1.43 EPS for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. raised its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.